Trials / Terminated
TerminatedNCT01140503
A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With Dermatomyositis
An Open Label Study Evaluating the Safety and Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Dermatomyositis
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the safety and efficacy of an oral medicine (called apremilast) for treating skin involvement in patients with the disease dermatomyositis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apremilast | Apremilast 20mg PO BID |
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2011-08-01
- Completion
- 2011-09-01
- First posted
- 2010-06-09
- Last updated
- 2015-03-04
- Results posted
- 2015-03-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01140503. Inclusion in this directory is not an endorsement.